The US health insurance program Medicare is considering plans to extend its coverage to include CAR-T cell therapies. The programme is set to announce a final decision within years on whether to incorporate the personalised treatment platform, with two CAR-T blood cancer products already having been approved by the Food and Drug Administration. Proponents of the plan argue that incorporating the treatments would save money in the long-term, despite their high upfront costs, due to their effectiveness.
The US health insurance program Medicare is considering plans to extend its coverage to include CAR-T cell therapies. The programme is set to announce a final decision within the next few weeks on whether to incorporate the personalised treatment platform, with two CAR-T blood cancer products already having been approved by the Food and Drug Administration. Proponents of the plan argue that incorporating the treatments would save money in the long-term, despite their high upfront costs, due to their effectiveness.